Gestational diabetes and the risk of late stillbirth: a case-control study from England, UK.


Journal

BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741

Informations de publication

Date de publication:
Jul 2019
Historique:
accepted: 31 01 2019
pubmed: 21 3 2019
medline: 18 6 2019
entrez: 21 3 2019
Statut: ppublish

Résumé

To explore the separate effects of being 'at risk' of gestational diabetes mellitus (GDM) and screening for GDM, and of raised fasting plasma glucose (FPG) and clinical diagnosis of GDM, on the risk of late stillbirth. Prospective case-control study. Forty-one maternity units in the UK. Women who had a stillbirth ≥28 weeks of gestation (n = 291) and women with an ongoing pregnancy at the time of interview (n = 733). Causal mediation analysis explored the joint effects of (i) 'at risk' of GDM and screening for GDM and (ii) raised FPG (≥5.6 mmol/l) and clinical diagnosis of GDM on the risks of late stillbirth. Adjusted odds ratios (aOR) were estimated by logistic regression adjusted for confounders identified by directed acyclic graphs. Screening for GDM and FPG levels RESULTS: Women 'at risk' of GDM, but not screened, experienced 44% greater risk of late stillbirth than those not 'at risk' (aOR 1.44, 95% CI 1.01-2.06). Women 'at risk' of GDM who were screened experienced no such increase (aOR 0.98, 95% CI 0.70-1.36). Women with raised FPG not diagnosed with GDM experienced four-fold greater risk of late stillbirth than women with normal FPG (aOR 4.22, 95% CI 1.04-17.02). Women with raised FPG who were diagnosed with GDM experienced no such increase (aOR 1.10, 95% CI 0.31-3.91). Optimal screening and diagnosis of GDM mitigate the higher risks of late stillbirth in women 'at risk' of GDM and/or with raised FPG. Failure to diagnose GDM leaves women with raised FPG exposed to avoidable risk of late stillbirth. Risk of #stillbirth in gestational diabetes is mitigated by effective screening and diagnosis.

Identifiants

pubmed: 30891907
doi: 10.1111/1471-0528.15659
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

973-982

Subventions

Organisme : Department of Health
ID : CS-2013-13-009
Pays : United Kingdom
Organisme : Action Medical Research, Cure Kids and Sands
ID : GN2156

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 Royal College of Obstetricians and Gynaecologists.

Auteurs

T Stacey (T)

School of Healthcare, University of Leeds, Leeds, UK.

Pwg Tennant (P)

Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
School of Medicine, University of Leeds, Leeds, UK.
The Alan Turing Institute, London, UK.

Lme McCowan (L)

Department of Obstetrics and Gynaecology, The University of Auckland, Auckland, New Zealand.

E A Mitchell (EA)

Department of Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand.

J Budd (J)

Maternal and Fetal Health Research Centre, School of Medical Sciences, Faculty of Biological, Medical and Human Sciences, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

M Li (M)

Department of Obstetrics and Gynaecology, The University of Auckland, Auckland, New Zealand.

Jmd Thompson (J)

Department of Obstetrics and Gynaecology, The University of Auckland, Auckland, New Zealand.
Department of Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand.

B Martin (B)

Birmingham Women's Hospital NHS Foundation Trust, Birmingham, UK.

D Roberts (D)

Liverpool Women's Hospital NHS Foundation Trust, Liverpool, UK.

Aep Heazell (A)

Maternal and Fetal Health Research Centre, School of Medical Sciences, Faculty of Biological, Medical and Human Sciences, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH